Revenue surged 82% year-over-year to $29.4 million.

Record 60% gross margin and expanded ADDI partnership position the company for 59% annual growth, despite widening net losses and near-term margin fluctuations.

Alamar Biosciences stock has gained 27.2% year to date, yet the company currently screens as expensive on Simply Wall St's broader valuation checks. That mix of strong recent returns and a low value score raises questions about how much optimism is already reflected in the share price. The 27.2% gain year to date suggests investors have been willing to pay up for Alamar Biosciences, and that recent enthusiasm is now central to the valuation story. Upcoming financial results and new product...

Alamar Biosciences (NASDAQ:ALMR) reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company’s first earnings call since completing its April initial public offering. Chief

The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.

The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.

If you’re an Alamar Biosciences (ALMR) shareholder, Friday was a good day. The stock climbed +7.3%, closing the session at a new 52-week high of $28.42. That’s a tidy gain on a day when the S&P 500 barely nudged up +0.4% and some key industry peers actually lost ground.

What Alamar Biosciences stock is telling you right now Alamar Biosciences (ALMR) has attracted fresh attention after recent trading left the stock with a last close of US$23.01 and a year to date gain of 4.59%, against mixed shorter term returns. For context, the stock was roughly flat over the past day, gained 0.17%, but declined 3.48% over the past week. Month and past 3 months performance data is not available, so short term momentum beyond these windows is harder to compare. See our...

Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls